OBIO Pre-CAAP Company: Proteocyte Announces Changes to Board of Directors for 2018

Proteocyte Diagnostics, a company that has designed a platform technology to predict your risk of developing cancer, announces the restructuring and expansion of the Board of Directors with the addition of James Appleyard, Laurence Hicks,  Peter G. Schulam and Carlo Sistilli. Proteocyte is also pleased to announce that Robert Lawrie, the Chair of the Canadian Cancer Society, has agreed to join the Board. 

Our new board members, with their variety of experience across multiple industries, strengthens Proteocyte and will help us achieve the significant milestones ahead. Our experienced leadership team, our global Clinical Advisory Board, and now our new additions to the Board of Directors sets us up for success.”
— John Davis, President & CEO, Proteocyte Diagnostics